196 results about "Osteosarcoma" patented technology

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

The invention discloses a near-infrared light response titanium-based implant as well as a preparation method and application thereof, and belongs to the technical field of medical materials. The near-infrared light response titanium-based implant provided by the invention comprises a porous titanium substrate, the TiO2 nanotube array is formed on the surface of the porous titanium substrate; the first photo-thermal coating layer is formed on the TiO2 nanotube array; the second photo-thermal coating is formed on the first photo-thermal coating; wherein the first photo-thermal coating is a ZIF-8 coating; and the second photo-thermal coating is a carbon nanotube coating. Through the double-layer photo-thermal system design of the ZIF-8 coating, the photo-thermal conversion efficiency is greatly improved, the controllable photo-thermal response capacity, the long-acting antibacterial and anti-tumor capacity and the dynamic osseointegration capacity are achieved, and the excellent osteosarcoma treatment effect is achieved.

This invention relates to the field of anticancer drugs, and more particularly to an indole-3-aryl ketone derivative, its preparation method, and its applications. The indole-3-aryl ketone derivative is compound I-VI, which can be used to prepare drugs for the prevention and / or treatment of cancer, including at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer, and esophageal cancer. This invention screened the activity of various compounds and, for the first time, discovered that compound I-VI exhibits excellent inhibitory activity against multiple different types of human cancer cells, providing a potential option for broad-spectrum anticancer drugs.

The invention belongs to the technical field of osteosarcoma prognosis prediction, and relates to a multi-view TSK deep learning model based on Dirichlet distribution and application thereof, a multi-view data module in the model transmits view features to a multi-view TSK fuzzy system module, and the multi-view TSK fuzzy system module maps the input view features into Dirichlet evidence parameters and transmits the Dirichlet evidence parameters to a Dirichlet distribution module; the Dirichlet distribution module establishes a classification probability representation space according to Di richlet evidence parameters and transmits the classification probability representation space to the uncertainty quantification module, the uncertainty quantification module quantifies the classification probability into view decision confidence through a dynamic evidence aggregation engine, self-adaptive weighted fusion is carried out on the view decision confidence through a combination rule, and the view decision confidence is obtained. And a multi-view TSK deep learning model is applied to osteosarcoma prognosis prediction, so that the prediction accuracy is improved.

The invention discloses a limonin compound and application thereof in preparation of a medicine for preventing and / or treating cancers. The structure of the limonin compound is shown as a formula I or II. The cancer is at least one of breast cancer, liver cancer, gastric cancer, esophageal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, prostatic cancer, nasopharynx cancer, cervical cancer, ovarian cancer, kidney cancer and skin cancer. According to the invention, activity screening is carried out on various natural product extracts, it is found for the first time that limonin compounds with structural formulas I and II have excellent inhibitory activity on various different types of human cancer cells, and an optional scheme is provided for broad-spectrum anti-cancer drugs. Related results also show that the compound provided by the invention can inhibit migration and invasion ability of breast cancer cells, promote cell apoptosis and retard a cell cycle. The limonin compound applied in the invention is derived from mallotus oblongifolius, the source is wide, and the production cost is low.

The invention relates to the technical field of image recognition, in particular to an osteosarcoma image intelligent recognition and classification method and system based on an image recognition model. The method comprises the following steps: collecting a tumor image and carrying out multi-sequence disturbance equilibrium enhancement to generate an enhanced block tumor image, then obtaining a color standardized image through color space transformation remapping, then extracting a tumor region image and carrying out contrast inversion processing, reconstructing a tumor feature image, and finally, carrying out multi-sequence disturbance equilibrium enhancement on the tumor feature image. Based on a preset image recognition model, tumor edge features are recognized, the edge rule degree is determined, preliminary classification is carried out, a benign tumor image is obtained, surrounding metabolite signal features of the benign tumor image are analyzed, a benign reference group is formed through combination, metabolism state comparison is carried out on tumor feature images, and metabolism difference data are generated. And performing category correction according to the metabolic state mapping data so as to identify the osteosarcoma category. According to the invention, intelligent analysis of tumor features is realized, the image processing flow is optimized, and the processing efficiency is improved.

The invention relates to the field of anti-cancer drugs, in particular to an indole-3-aryl ketone derivative as well as a preparation method and application thereof. The indole-3-aryl ketone derivative is a compound I-VI, the indole-3-aryl ketone derivative can be used for preparing drugs for preventing and / or treating cancers, and the cancers comprise at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer. According to the invention, activity screening is carried out on various compounds, the fact that the compounds I-VI have excellent inhibitory activity on various different types of human cancer cells is found for the first time, and an optional scheme is provided for broad-spectrum anti-cancer drugs.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly ovarian cancer, osteosarcoma, colon cancer, breast cancer, skin cancer, melanoma, esophageal cancer, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESSC), particularly esophageal cancer, or EAC or ESSC.

The invention discloses a pelvic soft osteosarcoma MRI (Magnetic Resonance Imaging) segmentation method based on edge-guided multi-scale fusion. The method comprises the following steps: firstly, acquiring an MRI image of a patient with soft osteosarcoma of pelvis, and preprocessing the image; and then, constructing a pelvic soft osteosarcoma MRI segmentation network model, namely an EMU-Net segmentation network, based on edge-guided multi-scale fusion. And training the network by using the preprocessed training data, inputting a pelvic soft osteosarcoma MRI image to be segmented into the trained network, outputting a corresponding segmentation probability graph, and obtaining a final tumor segmentation mask by setting a threshold value. The method not only effectively overcomes the clinical segmentation bottleneck, but also realizes full-automatic and high-efficiency precise segmentation by means of an end-to-end deep learning architecture, and has remarkable advantages in the aspects of precision and robustness.

The invention relates to the technical field of image recognition, in particular to a multi-scale osteosarcoma CT image lesion area detection method based on feature distillation. The method comprises the following steps: acquiring a multi-scale osteosarcoma CT image and an attachment area image, performing forged image difference reduction to generate a unified CT image, reconstructing a three-dimensional tumor body form, extracting a bone attachment structure, performing relocation registration to obtain tumor body relocation data, and then generating a simulation attachment area framework based on the data, the method comprises the following steps: performing static feature distillation on a three-dimensional tumor body form to obtain an edge contour, defining an initial attachment area frame, performing feature comparison through a historical contour image to extract form change, evaluating the erosion degree of the attachment frame, and finally screening candidate lesion areas and positioning osteosarcoma lesion areas according to change areas. According to the invention, more efficient multi-source heterogeneous image data integration, more accurate three-dimensional tumor simulation reconstruction and clearer lesion area detection are realized.

The invention relates to the field of antitumor drugs, in particular to a thiophene acetyl tetrahydro-beta-carboline compound and application thereof. The thiophene acetyl tetrahydro-beta-carboline compound or the pharmaceutically acceptable salt thereof, and the pharmaceutical composition containing the compound can be used for preparing medicines for preventing and / or treating various cancers. The cancer is at least one of breast cancer, lung cancer, osteosarcoma, melanoma, gastric cancer, pancreatic cancer, kidney cancer, glioma and ovarian cancer. Activity screening is carried out on various compounds, it is found for the first time that the 12 compounds provided by the invention have remarkable broad-spectrum inhibitory activity on various human cancer cell lines, and key candidate compounds are provided for developing novel anti-cancer drugs.

The invention relates to application of an SLC30A9 inhibitor in preparation of an anti-tumor medicine, and belongs to the technical field of biological medicines. The invention provides an application of an SLC30A9 inhibitor in preparation of an anti-tumor drug. The expression of SLC30A9 is down-regulated to activate a cGAS-STING-NF-kappa B pathway, so that apoptosis of osteosarcoma cells is promoted, killing of the osteosarcoma cells by MTX is enhanced, and sensitivity of the osteosarcoma cells to MTX chemotherapy is recovered. Through combined application of SLC30A9 knock-down, a cGAS-STNG-NF-kappa B pathway agonist and MTX for chemotherapy, the killing effect of MTX on osteosarcoma cells can be remarkably enhanced, tumor cell proliferation is inhibited, and the treatment effect is improved. The core effect of the SLC30A9 in an osteosarcoma chemotherapy drug resistance mechanism is defined, and a theoretical basis and a technical support are provided for subsequent development of targeted drugs aiming at a cGAS-STNG-NF-kappa B pathway.

GD2 specific chimeric antigen receptor effector cells for the treatment of solid tumors, possibly in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor. The invention relates to a GD2-specific chimeric antigen receptor (GD2. CAR) effector cell for use in the treatment of solid tumors, in particular in the treatment of extracranial GD2 + tumors, such as soft tissue sarcoma and osteosarcoma, neuroblastoma, melanoma, lung cancer, bladder cancer and retinoblastoma, and brain tumors. In addition, the present invention also relates to the use of the GD2. CAR genetically modified effector cell in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor for the treatment of solid tumors.

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate RSK signaling. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin to inhibit RSK. Some aspects of the invention provide methods of using N-desmethyl ruboxistaurin in the treatment of subjects with cancer, including breast cancer, ovarian cancer, prostate cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, melanoma, osteosarcoma, myeloproliferative neoplasms, leukemia, and bladder cancer. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, inhibits RSK and shows a safety profile that supports its long-term use.

The present invention discloses an osteosarcoma molecular marker and its application. The osteosarcoma molecular marker is spindle and centriole associated protein 1, the amino acid sequence of which is shown in SEQ ID No: 1. Tissue sequencing revealed that the expression level of spindle and centriole associated protein 1 having the amino acid sequence of SEQ ID No: 1 was significantly higher in osteosarcoma tissue than in normal bone tissue. After knocking down the protein, osteosarcoma proliferation, invasion, and migration were significantly inhibited, and apoptosis was increased. Therefore, the molecular marker can be used as an osteosarcoma marker, playing a role in assisting the diagnosis of osteosarcoma in its early stages, enabling patients to receive timely treatment and preventing the problem of osteosarcoma metastasis.

This disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof, methods for preparing the same, and their use in the treatment and / or diagnosis of cancers such as neuroblastoma, prostate cancer, pancreatic cancer, leukemia, osteosarcoma, hepatoblastoma, lung cancer, colon cancer, breast cancer, skin cancer, thyroid cancer, and / or rhabdoid cancer. JPEG2026522940000099.jpg50170

The disclosure relates to the field of gene therapy for the treatment of an osteosarcoma using splice-switching oligonucleotides. Increased expression of INSR-A, an isoform frequently expressed in cancer, can effectively evade current therapeutic mechanisms and contribute to resistance in cancer patients. As a means to address the ability of cancer to evade therapies through this mechanism, Applicant provides a polynucleotide comprising a promoter, for example a U7 or a U1 promoter, and a first splice-switching oligonucleotide (SSO) that targets a regulatory element of an insulin receptor (JR).

The invention provides application of a bisindole compound XQ-016 in treatment of osteosarcoma, and belongs to the technical field of biological medicines. The bisindole compound XQ-016 can inhibit proliferation, migration and invasion of tumor cells by adjusting an STAT3 / p53 signal channel, inducing G1 phase cell cycle arrest and inhibiting MMP2 / MMP9 expression, shows remarkable anti-tumor activity, is a promising treatment choice in tumor treatment, and can be used as an effective component in anti-tumor drugs.

The invention relates to a compound for inhibiting osteosarcoma cell invasion and metastasis capability and application of the compound, in particular to application of a PAC channel inhibitor to preparation of a composition or a preparation, and the composition or the preparation is used for preventing and / or treating osteosarcoma. It is found for the first time that PAC channel inhibitors (such as Evans blue (EB), trypan blue (TB), aniline blue (AB), Coomassie brilliant blue (CBB), Cicago sky blue 6B (CSB), direct blue 71 (DB-71) and thiazole yellow (TY)) effectively prevent and / or treat osteosarcoma by inhibiting the activity of PAC channels.

The application discloses a kind of thieno [2, 3-c] pyrazole compounds in preparation antitumor drug purposes, belong to pharmaceutical chemistry technical field.The application provides a kind of small molecule skeleton thieno [2, 3-c] pyrazole compound I and II, compound I is 2-oxo benzo [d] [1, 3] oxathiole-6-yl 1-(3-fluorophenyl)-3-methyl-1H-thieno [2, 3-c] pyrazole-5-carboxylate.Compound II is 1-(4-chlorophenyl)-N-[4-((4-ethylpiperazine-1-yl)methyl)phenyl]-3-methyl-1H-thieno [2, 3-c] pyrazole-5-formyl.Both have strong antitumor activity.Compound II has strong inhibition to a variety of human tumor cells, such as bone sarcoma MG63, breast cancer HCC1806, liver cancer LM3, lung cancer A549, colorectal cancer HCT-8 and the like, provides new candidate compounds for broad-spectrum antitumor drugs.

The invention belongs to the technical field of diagnosis and treatment of osteosarcoma, and particularly relates to application of a C1QTNF1-AS1 / miR-346-LDHA / PDK regulation axis in diagnosis and treatment of osteosarcoma, a full-chain technical system of'diagnostic marker-double-target intervention-clinical transformation 'is constructed on the basis of the C1QTNF1-AS1 / miR-346-LDHA / PDK regulation axis, and accurate diagnosis and metabolic intervention of osteosarcoma are realized through multi-dimensional experimental verification; in the diagnosis, a C1QTNF1-AS1 / miR-346 combined detection kit based on qPCR is applied to early screening of osteosarcoma; according to the treatment application, the C1QTNF1-AS1 adenovirus and the miR-346 lipidosome are used in a combined manner, and LDHA and PDK1 are synchronously inhibited, so that the Warburg effect related metabolic flux is intervened.

The present invention provides a composition for use in a method of treating osteosarcoma, Ewing sarcoma and / or a metastatic cancer originating from osteosarcoma or Ewing sarcoma. The present invention also provides a method of treating a cancer selected from the group consisting of osteosarcoma, Ewing sarcoma, a metastatic cancer originating from an osteosarcoma and a metastatic cancer originating from Ewing sarcoma.

The invention relates to application of Nogo-B protein in preparation of a medicine serving as an anti-osteosarcoma target spot. The invention discloses an alpha-hydroxyl / alkoxy / amino-beta-amino derivative, a synthesis method thereof and application of Nogo-B protein serving as a new osteosarcoma target, an osteosarcoma diagnostic reagent and a small-molecule inhibitor 4v serving as an osteosarcoma targeting drug. A diazo compound, water / alcohol / amide and imine are used as raw materials, rhodium acetate is used as a catalyst, a product is obtained in an organic solvent through a one-step reaction with high selectivity and high yield, then the small-molecule inhibitor 4v is obtained through osteosarcoma cell surface screening, a new osteosarcoma target Nogo-B is proposed based on a proteomics analysis technology, and the new target Nogo-B is used for inhibiting osteosarcoma. The effects of inhibiting cell proliferation and migration and tumor growth can be achieved through experiments such as knockout of Nogo-B protein. The invention discloses a novel application of Nogo-B protein. The Nogo-B protein is used for preventing, relieving and treating osteosarcoma and osteosarcoma-related complications of individuals in need. Also disclosed are methods of diagnosing, treating, and monitoring osteosarcoma or methods of inhibiting osteosarcoma, and methods of screening for osteosarcoma inhibitors.

The present invention belongs to the technical field of pharmaceutical chemistry, and discloses a paeonol Mannich base-rhein conjugate, a preparation method thereof and an application thereof. The conjugate is a compound represented by the general formula (I) or (II) or a pharmaceutically acceptable salt thereof. Compared with the clinically commonly used anti-tumor drugs fluorouracil and paeonol, the conjugate of the present invention has significantly higher in vitro proliferation inhibitory activities against human liver cancer cells (HepG2) and human lung cancer cells (A549), and the in vitro proliferation inhibitory activities of most compounds against human cervical cancer cells (Hela), human colon cancer cells (HT29) and human osteosarcoma cells (U2OS) are significantly better than those of fluorouracil and paeonol, indicating excellent anti-tumor effects. Moreover, the conjugate of the present invention has good water solubility and is expected to be applied to the treatment of various cancers such as cervical cancer, colon cancer, osteosarcoma, lung cancer or liver cancer, and has broad clinical application prospects.

The present disclosure provides compounds according to Formula I and pharmaceutically acceptable salts thereof, as well as compositions including such compounds and a pharmaceutically acceptable carrier or excipient. Further provided are methods of inactivating SIRT6 with compounds of Formula I as well as compounds of Formula III, W2—R2—Y—R3, as described herein. In addition, the present technology provides methods of treatment using such compounds to lower LDL levels, lower triglyceride levels, and / or increase glucose tolerance in a subject, and / or to inhibit proliferation of ovarian, colorectal, hepatocellular, non-small cell lung, glioblastoma, osteosarcoma, pancreatic, and skin cancer cells, and / or inhibit liver and / or kidney fibrosis, and / or promote corneal epithelial wound healing.

The invention relates to anti-GD2 antibody-drug conjugates, compositions comprising the same and uses thereof in the treatment of osteosarcoma.

The present invention discloses a composite nanoparticle for treating osteosarcoma and a preparation method thereof. The composite nanoparticle uses porous silica nanoparticles or copper-containing porous silica nanoparticles as a carrier to encapsulate ilisimol. The preparation method of the composite nanoparticle for treating osteosarcoma comprises the following steps: uniformly mixing the porous silica nanoparticles or copper-containing porous silica nanoparticles with a dimethyl sulfoxide solution of ilisimol, stirring in the dark at room temperature for 23 to 25 hours, centrifuging for 14 to 16 minutes, collecting the precipitate, and freeze-drying for 23 to 26 hours to obtain the composite nanoparticle for treating osteosarcoma. The composite nanoparticle provided by the present invention is obtained by encapsulating ilisimol using porous silica nanoparticles or copper-containing porous silica nanoparticles as a carrier. The resulting composite nanoparticle induces copper cell death in osteosarcoma, can significantly inhibit osteosarcoma cell growth, achieve osteosarcoma treatment, and prolong patient survival, providing a new direction for the treatment of osteosarcoma.

The invention discloses an application of targeted improvement of a high-potassium microenvironment in osteosarcoma immunotherapy, vanadium disulfide nano-particles are synthesized by taking vanadyl acetylacetonate as a raw material and adopting a high-temperature oil phase method, the particles can be accelerated to decompose at 42 DEG C or above so as to release hydrogen sulfide and vanadate, the vanadate can be specifically combined with E2 conformation of Na < + >-K < + >-ATP enzyme, and thus the stability of the particles is improved. According to the present invention, the HSP protein is released, the conversion of the HSP protein to E1 conformation is blocked, the continuous inward flow of K < + > is inhibited, such that the potassium ion concentration in the T cell is reduced, the function inhibition on the T cell is relieved, and the released hydrogen sulfide can further enhance the thermal effect by inhibiting the HSP protein so as to form the ion regulation-immune activation dual mechanism to improve the T cell killing ability. According to the scheme, the high potassium ion level of the osteosarcoma microenvironment is regulated and controlled through vanadate, hydrogen sulfide can enhance immune response and improve the anti-tumor function of T cells by enhancing the heat effect and the synergistic effect of vanadate, and an efficient and low-toxicity new strategy is provided for osteosarcoma treatment.

The invention relates to a polyethylene glycol medicine as well as a preparation method and application thereof. Specifically, the invention relates to a compound as shown in a formula I or pharmaceutically acceptable salt thereof, an intermediate compound as shown in a formula II-XX, a method for preparing the compound, and an application of the compound in tumor resistance. Biological tests show that the compound has a remarkable inhibition effect on tumors such as breast cancer, non-small cell lung cancer, melanoma, oral squamous cell carcinoma and osteosarcoma.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly ovarian cancer, gastrointestinal cancer, pancreatic cancer, prostate cancer, stromal cancer, osteosarcoma, colon cancer, breast cancer, skin cancer, melanoma, esophageal cancer, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESSC), particularly esophageal cancer, or EAC or ESSC.